Make an Inquiry
Accelerating Schistosomiasis Drug Development

Schistosomiasis remains a significant global health challenge, with limited therapeutic options and a pressing need for innovative solutions. Ace Therapeutics is dedicated exclusively to advancing drug development for Schistosomiasis, serving as a specialized partner for organizations seeking targeted expertise in this neglected disease area. Ace Therapeutics offers a comprehensive suite of preclinical services, encompassing target validation, lead optimization, and IND-enabling studies. Our scientific team brings deep domain knowledge in parasitology and drug discovery, supported by advanced assay platforms and state-of-the-art laboratory infrastructure. Every stage of our workflow is guided by rigorous scientific standards and full alignment with international regulatory requirements, ensuring the generation of robust, decision-enabling data. By integrating scientific excellence with operational efficiency, Ace Therapeutics accelerates the path from discovery to clinical readiness. Our unwavering commitment is to deliver high-quality, actionable results that drive therapeutic breakthroughs against Schistosomiasis and improve patient outcomes worldwide.

What is SchistosomiasisTargets for SchistosomiasisDrug Discovery and Development ServicesWhy Choose Us

What is Schistosomiasis

Schistosomiasis, or bilharzia, is a parasitic disease caused by trematode worms of the genus Schistosoma. Infection occurs when larval forms released by freshwater snails penetrate human skin during contact with contaminated water. The parasites mature in the venous system, with adult worms residing in the mesenteric or pelvic veins, depending on the species. The disease’s pathophysiology is driven by the immune response to schistosome eggs deposited in tissues, resulting in granulomatous inflammation and progressive fibrosis. Chronic infection can affect the intestines, liver, urinary tract, and, rarely, the central nervous system, leading to significant morbidity. Clinically, schistosomiasis presents with a range of symptoms, from acute fever and rash (Katayama syndrome) to chronic complications such as abdominal pain, diarrhea, hematuria, portal hypertension, and increased risk of bladder cancer. Diagnosis relies on identifying characteristic eggs in stool or urine samples, supported by serological and antigen detection assays, especially in low-intensity infections. Imaging and biopsy may assist in assessing organ involvement. Praziquantel is the mainstay of treatment, effective against all major Schistosoma species, and is used both for individual therapy and mass drug administration. Early diagnosis and treatment are crucial to prevent severe complications and reduce disease transmission.

Launched Drugs

Structure Generic Name CAS Registry Number Molecular Formula Molecular Weight
img-55268-74-1-praziquantel-rec-inn-usan-ban praziquantel (Rec INN; USAN; BAN) 55268-74-1 C19 H24 N2 O2 312.406

Learn More

Targets for Schistosomiasis

Targets in Clinical or Later Phases of Development

Target Name Gene Symbol
Transient Receptor Potential Cation Channel (TRP) (nonspecified subtype)
toll like receptor 4 TLR4

Schistosomiasis pathogenesis is driven by a network of molecular targets that orchestrate immune modulation, tissue remodeling, and parasite survival. Key immune targets include Interleukin 1 Beta (IL1B), a pro-inflammatory cytokine central to granuloma formation and tissue damage, and Toll Like Receptor 4 (TLR4), a pattern recognition receptor that senses schistosome antigens and initiates inflammatory cascades. Signal Transducer and Activator of Transcription 6 (STAT6) is pivotal for Th2 immune polarization and alternative macrophage activation, both critical for granulomatous inflammation. In parallel, Transforming Growth Factor Beta Receptor 1 (TGFBR1) mediates fibrogenic signaling in hepatic stellate cells, promoting collagen deposition and liver fibrosis. Unique to the parasite, Thioredoxin Glutathione Reductase (TGR) maintains redox homeostasis, enabling Schistosoma species to survive oxidative stress imposed by the host immune response. Therapeutically, these targets offer diverse intervention points. IL1B and TLR4 antagonists, already in use or under evaluation for other inflammatory diseases, show promise in modulating the excessive immune response in schistosomiasis. STAT6 inhibitors are being explored to disrupt Th2-driven pathology. TGFBR1 inhibitors, some in clinical development for fibrotic conditions, may attenuate schistosomiasis-induced liver fibrosis. Notably, TGR represents a parasite-specific vulnerability; inhibitors like auranofin have demonstrated potent anti-schistosomal activity in preclinical studies. Collectively, these targets are not only central to disease mechanisms but also serve as biomarkers for disease progression and treatment efficacy, supporting the rational design of novel therapeutics.

Learn More

Drug Discovery and Development Services

In Vitro Efficacy Testing ServicesIn Vivo Model DevelopmentPK/PD Study ServicesIn Vivo Toxicity Assessment ServicesBiomarker Analysis Services
In Vitro Efficacy Testing Services

Online Inquiry

Our In Vitro Efficacy Testing Service accelerates schistosomiasis drug discovery by providing robust biochemical and cell-based assays for key parasite targets, including proteases, epigenetic enzymes, and signaling proteins. Utilizing advanced methods such as fluorescent and luminescent readouts, substrate-based enzymatic assays, and histone modification analysis, we deliver precise measurements of compound potency. Critical pharmacological parameters like IC-50 and MIC are determined to guide lead selection and optimization. Our tailored platforms enable rapid, sensitive evaluation of candidate therapeutics, supporting informed decision-making and efficient advancement of novel antischistosomal agents targeting essential pathways in Schistosoma biology.

Androgen Receptor Creb Binding Protein
Fatty Acid Amide Hydrolase Histone Deacetylase 6
Histone Deacetylase 8 Prostaglandin-Endoperoxide Synthase 1
Thioredoxin Reductase 1

Learn More

Why Choose Us

At Ace Therapeutics, we are dedicated to advancing the fight against Schistosomiasis through our specialized expertise in research and drug development. Our professional teams comprise experienced scientists and industry experts who possess deep knowledge of Schistosomiasis biology and the unique challenges it presents. Leveraging advanced technology platforms, Ace Therapeutics delivers innovative solutions that accelerate the discovery and preclinical development of novel therapeutics. Our proven track record in preclinical drug development services is built on reliability, transparency, and a commitment to excellence, ensuring that each project receives meticulous attention and scientific rigor. We adhere to the highest quality standards and maintain strict regulatory compliance throughout every stage of development, providing our partners with confidence and peace of mind. At Ace Therapeutics, we are passionate about making a meaningful impact in the field of Schistosomiasis therapeutics, working tirelessly to bring new, effective treatments closer to those in need. Choose Ace Therapeutics as your trusted partner and benefit from our unwavering dedication, professionalism, and expertise in Schistosomiasis drug development.

FAQs for Our Services

Q: What are the major preclinical research challenges specific to Schistosomiasis drug development?

A: Schistosomiasis presents unique preclinical challenges, including the complexity of the parasite's life cycle, the need for relevant animal models, and limited availability of standardized in vitro assays. Our company addresses these challenges by utilizing validated animal models that mimic human infection, optimizing parasite cultivation techniques, and developing robust screening assays to evaluate compound efficacy and selectivity.

Q: What are the key regulatory considerations in preclinical development for Schistosomiasis therapies?

A: Regulatory agencies such as the FDA and EMA require comprehensive safety and efficacy data for neglected tropical diseases like Schistosomiasis. This includes rigorous toxicological profiling, pharmacokinetic/pharmacodynamic studies, and demonstration of efficacy in appropriate models. Our team ensures compliance with ICH and WHO guidelines, providing clients with detailed study reports and regulatory support throughout the IND-enabling process.

Q: What technical aspects are critical when conducting preclinical research for Schistosomiasis?

A: Technical success in Schistosomiasis research hinges on expertise in parasite biology, access to life stages of Schistosoma species, and proficiency in bioanalytical techniques. We offer specialized capabilities such as high-throughput screening, advanced imaging for parasite burden assessment, and molecular assays for mode-of-action studies. Our facilities are equipped to handle the unique biosafety requirements of Schistosoma research.

Q: What are the typical timeline and cost considerations for preclinical development of Schistosomiasis drugs?

A: Preclinical development for Schistosomiasis typically spans 12 to 24 months, depending on the complexity of the compound and required studies. Costs can vary significantly but generally range from $1 million to $5 million for comprehensive IND-enabling packages. We work closely with clients to optimize study design, minimize costs, and adhere to agreed timelines without compromising scientific rigor.

Q: What are the key success factors in developing new drugs for Schistosomiasis at the preclinical stage?

A: Success in Schistosomiasis drug development relies on early identification of potent and selective compounds, use of predictive in vitro and in vivo models, and a clear understanding of the parasite's biology. Our integrated approach combines medicinal chemistry, pharmacology, and toxicology to de-risk candidate selection and accelerate progression to clinical trials. Collaboration, transparency, and scientific excellence are at the core of our preclinical services.

Make an Inquiry
Important Links
Get in Touch with Us

Copyright © Ace Therapeutics. All rights reserved.